Gobernanza Regeneron Pharmaceuticals, Inc.

REGN

US75886F1075

Farmacéuticos

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 16/01/2026			Variación 5 días	Varia. 1 de enero.
733,04 ^USD	-1,20 %		-7,97 %	-5,03 %

16/01	Eylea de Bayer obtiene aprobación de la UE para la oclusión de la vena retiniana	MT
16/01	Algunas farmacéuticas muestran preocupación por riesgos legales en el programa acelerado de revisión de la FDA	RE

Comité Ejecutivo: Regeneron Pharmaceuticals, Inc.

Director

Funciones ocupadasDesde

Leonard Schleifer

73 años

Chief Executive Officer	08/01/1988
Founder	08/01/1988
President	08/01/1988

George Yancopoulos

66 años

Chief Tech/Sci/R&D Officer	01/01/2001
Founder	08/01/1988
President	01/01/2001

Andrew Murphy

68 años

Chief Tech/Sci/R&D Officer

01/01/2019

Melissa Lozner

Compliance Officer

01/01/2022

Jason Pitofsky

49 años

Comptroller/Controller/Auditor

05/02/2024

Johnathan Lancaster

Chief Tech/Sci/R&D Officer

01/01/2019

Mark Volpe

Comptroller/Controller/Auditor

01/01/2012

Maya Bermingham

General Counsel

01/01/2015

Bob McCowan

Chief Tech/Sci/R&D Officer

Christopher Fenimore

55 años

Director of Finance/CFO

05/02/2024

Sally A. Paull

Human Resources Officer

01/01/2016

Ned Braunstein

General Counsel

01/01/2009

Joseph LaRosa

67 años

General Counsel	06/09/2011
Corporate Secretary	06/09/2011

Ryan Crowe

Investor Relations Contact

Composición del Consejo de Administración: Regeneron Pharmaceuticals, Inc.

Administrador

ComitésDesde

George Yancopoulos

66 años

Chairman

09/06/2023

Christine Poon

73 años

Executive Committee	01/09/2006
Finance Committee Chair
Governance Committee	06/02/2024
Compensation Committee Chair	16/11/2010
Finance Committee	05/05/2011
Audit Committee	12/02/2024
Nominating Committee	06/02/2024

David Schenkein

68 años

Governance Committee	01/05/2015
Nominating Committee	01/05/2015
Compensation Committee
Governance Committee Chair
Nominating Committee Chair

Bonnie Bassler

63 años

Governance Committee	12/09/2016
Compensation Committee	30/07/2020
Governance Committee Chair
Nominating Committee Chair

N. Coles

65 años

Executive Committee	18/03/2011
Audit Committee	17/02/2017
Compensation Committee	04/04/2025

George Sing

76 años

Compensation Committee	08/01/1988
Audit Committee Chair	08/01/1988

Arthur Ryan

83 años

Audit Committee	01/01/2003
Governance Committee Chair	01/01/2003

Joseph Goldstein

85 años

Governance Committee

14/06/2019

Huda Zoghbi

71 años

Compensation Committee

12/09/2016

Michael Brown

85 años

Governance Committee

01/06/1991

Kathryn Guarini

54 años

Audit Committee

08/09/2023

Craig Thompson

73 años

Director/Board Member	03/10/2022
Independent Dir/Board Member	03/10/2022

Leonard Schleifer

73 años

Chairman

09/06/2023

Últimos Nombramientos: Regeneron Pharmaceuticals, Inc.

08/01	Anavex Life Sciences Corp nombra al Dr. Wolfgang Liedtke como vicepresidente sénior y director global de neurología	CI
20/05/25	RESUMEN DE PRENSA - Wall Street Journal - 20 de mayo	RE
28/04/25	Arrivent Biopharma Inc nombra a Merdad Parsey miembro de su consejo de administración	CI
23/07/24	BridgeBio Pharma, Inc. anuncia el nombramiento de Thomas Trimarchi, Ph.D., como presidente y director de operaciones	CI
31/01/24	Regeneron Pharmaceuticals, Inc. Nombra a Jason Pitofsky Contralor, se espera que ocurra el 5 de febrero de 2024	CI
30/01/24	Regeneron Pharmaceuticals, Inc. Nombra a Philip Gregory Vicepresidente Senior y Director de Regeneron Cell Medicines	CI
11/09/23	El director financiero de Regeneron Pharmaceuticals se jubilará en febrero	MT

Más noticias

Antiguos Directivos y Administradores: Regeneron Pharmaceuticals, Inc.

Insider

Funciones ocupadas

DesdeHasta

Robert Landry

Director of Finance/CFO	03/10/2013	05/02/2024
Corporate Officer/Principal	09/09/2013	03/10/2013

Marc Tessier-Lavigne

Director/Board Member	21/11/2011	01/09/2023
Independent Dir/Board Member	21/11/2011	01/09/2023

David Weinreich

Private Equity Investor

01/02/2016

01/08/2023

P. Vagelos

Chairman

01/01/1995

09/06/2023

Harold Brakewood

Corporate Officer/Principal

01/12/2015

01/12/2021

James Cassidy

Corporate Officer/Principal

01/02/2020

01/08/2021

Neil Graham

Corporate Officer/Principal

01/01/2009

01/01/2020

Jay Markowitz

Corporate Officer/Principal

05/01/2017

01/01/2020

Ke Andrew Yuan

Corporate Officer/Principal

01/01/2015

01/01/2019

Manisha A. Narasimhan

Investor Relations Contact

01/09/2011

01/11/2018

Aaron Ondrey

Corporate Officer/Principal

01/03/2010

01/11/2018

Phillip Gutry

Corporate Officer/Principal

01/06/2015

01/10/2018

Jesper Gromada

Corporate Officer/Principal

01/07/2012

01/10/2018

Charles A. Baker

Director/Board Member	01/02/1989	08/06/2018
Independent Dir/Board Member	01/02/1989	08/06/2018

Robert J. Terifay

Corporate Officer/Principal

26/02/2007

05/01/2018

Peter Powchik

Corporate Officer/Principal

01/10/2006

01/01/2018

Pamela A. Trail

Corporate Officer/Principal

01/08/2010

01/03/2017

Catherine Stehman-Breen

General Counsel

01/01/2015

01/03/2017

William J. Sasiela

Corporate Officer/Principal

01/01/2010

01/01/2017

Douglas S. McCorkle

Comptroller/Controller/Auditor

01/05/1998

31/12/2016

Kevin Bailey

Private Equity Investor

01/10/1991

01/01/2016

Robert Alexander Ingram

Director/Board Member	04/04/2014	10/11/2015
Independent Dir/Board Member	11/03/2015	10/11/2015

Murray Goldberg

Chief Administrative Officer	01/03/1995	31/03/2015
Director of Finance/CFO	01/03/1995	03/10/2013
Treasurer	01/03/1995	08/05/2013

Alan Shuldiner

Corporate Officer/Principal

16/10/2014

Eric M. Shooter

Director/Board Member	08/01/1988	30/01/2014
Founder	08/01/1988	30/01/2014
Independent Dir/Board Member	08/01/1988	30/01/2014
Corporate Officer/Principal	08/01/1988	02/09/2009

Hala Mirza

Public Communications Contact

01/01/2014

Julie Clark

Corporate Officer/Principal

01/05/2011

01/10/2012

Carrie Brownstein

Corporate Officer/Principal

01/08/2012

Jim Tripp

Director/Board Member

01/01/2007

01/01/2012

Daniel Brims

Corporate Officer/Principal

31/07/2011

Stuart A. Kolinski

General Counsel	01/09/2000	-
Corporate Secretary	01/09/2000	-

Michael Aberman

Investor Relations Contact

23/03/2010

Randall G. Rupp

Corporate Officer/Principal

01/07/1991

02/04/2008

Imogene Dunn

Corporate Officer/Principal

01/01/2003

01/01/2008

Beth Levine

Compliance Officer	01/01/2008	01/09/2022
Corporate Officer/Principal	01/01/2008	-

Alain Thibault

Chief Tech/Sci/R&D Officer	02/09/2009	14/12/2011
Corporate Officer/Principal	26/02/2007	02/09/2009

Michael E. Faerm

Corporate Officer/Principal

01/10/2004

Merdad Parsey

Chief Tech/Sci/R&D Officer

01/01/2002

01/01/2004

Kremena Simitchieva

Sales & Marketing

01/01/2004

Hao Zhou

Chief Tech/Sci/R&D Officer

31/12/2001

Fred Middleton

Director/Board Member	01/01/1988	01/01/2001
Director of Finance/CFO	01/01/1988	01/01/2001

William G. Roberts

Chief Tech/Sci/R&D Officer	01/05/1999	-
General Counsel	01/05/1999	-

Denny Lanfear

Corporate Officer/Principal

01/01/1991

01/01/1999

Prasad Inampudi

Corporate Officer/Principal

31/12/1998

Hans-Peter Guler

Corporate Officer/Principal

01/04/1998

Patrice Gilooly

Chief Operating Officer

01/01/1998

Peter S. DiStefano

Corporate Officer/Principal

01/01/1991

01/01/1997

Ronald M. Lindsay

Corporate Officer/Principal

01/01/1997

Gerald Underwood

Corporate Officer/Principal

01/01/1995

Christopher Chapman

Chief Tech/Sci/R&D Officer

01/01/1992

01/01/1994

Stephen Squinto

Corporate Officer/Principal

01/01/1989

01/01/1992

Neil Stahl

Chief Tech/Sci/R&D Officer	01/01/2015	-
Corporate Officer/Principal	01/01/1991	01/01/2015

Alfred G. Gilman

Director/Board Member	08/01/1988	-
Founder	08/01/1988	-
Independent Dir/Board Member	08/01/1988	-
Corporate Officer/Principal	08/01/1988	02/09/2009

Carrie Murray

Corporate Officer/Principal

Sondra Smyrnios

Corporate Officer/Principal

Justin Holko

Investor Relations Contact

Gene Zhu

Corporate Officer/Principal

Robert Lisicki

Corporate Officer/Principal

Joseph Ricculli

Public Communications Contact

Matt I. Hermann

Corporate Officer/Principal

Brendan Classon

Corporate Officer/Principal

Peter G. Dworkin

Public Communications Contact

15/12/2009

Charles Poole

Public Communications Contact

Fredric D. Price

Chief Administrative Officer	-	-
Director of Finance/CFO	-	-

Joseph Pantginis

Corporate Officer/Principal

Eric S. Furfine

Corporate Officer/Principal

Paul F. Lubetkin

General Counsel	-	-
Corporate Secretary	-	-

Paul Lin

Corporate Officer/Principal

Christian Rommel

Chief Tech/Sci/R&D Officer	-	-
Corporate Officer/Principal	-	-

Catharine E. Johnson

Corporate Officer/Principal

Alexandra Bowie

Public Communications Contact

Steven E. Buchholz

Corporate Officer/Principal

Weng Tao

Corporate Officer/Principal

Avner Ingerman

Corporate Officer/Principal

Janet van Adelsberg

Corporate Officer/Principal

Terence E. Ryan

Corporate Officer/Principal

Potoula Gjidija

Public Communications Contact

Arleen Goldenberg

Public Communications Contact

Sean Stevens

Corporate Officer/Principal

Distribución por Edad de los Ejecutivos

Paridad de género

Hombre	26
Mujer	6

De los cuales Comité Ejecutivo

Hombre	11
Mujer	3

De los cuales Directores

Hombre	12
Mujer	1

Revisiones

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Regeneron Pharmaceuticals, Inc. se especializa en la investigación, el desarrollo, la producción y la venta de medicamentos utilizados en el tratamiento de enfermedades oftalmológicas e inflamatorias y cánceres. Las ventas netas se desglosan por tipo de ingresos de la siguiente manera: - ingresos procedentes de la venta de productos (53,7%); - ingresos procedentes de acuerdos de colaboración (42,7%): colaboración con Sanofi (74,8% de los ingresos), Bayer (24,7%) y otros (0,5%); - ingresos por ventas de licencias tecnológicas y servicios de investigación subcontratados (3,6%). A finales de 2024, el grupo contaba con una cartera de aproximadamente 40 productos en desarrollo clínico.

Empleados

15.222

Sector

Farmacéuticos

Agenda

30/01 - Q4 2025 Publicación de resultados

Más información sobre la empresa